---
title: "Oncology Institute - CW22 | 10-Q: FY2025 Q1 Revenue: USD 104.41 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/240231902.md"
datetime: "2025-05-14T20:25:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/240231902.md)
  - [en](https://longbridge.com/en/news/240231902.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/240231902.md)
---

# Oncology Institute - CW22 | 10-Q: FY2025 Q1 Revenue: USD 104.41 M

Revenue: As of FY2025 Q1, the actual value is USD 104.41 M.

EPS: As of FY2025 Q1, the actual value is USD -0.21.

### Patient Services Segment

-   **Revenue**: $53,068 for the three months ended March 31, 2025, compared to $52,453 for the same period in 2024, representing a 1.2% increase.
-   **Direct Costs**: $47,080 for the three months ended March 31, 2025, compared to $49,497 for the same period in 2024, representing a 4.9% decrease.
-   **Operating Income**: $4,515 for the three months ended March 31, 2025, compared to $1,723 for the same period in 2024.

### Dispensary Segment

-   **Revenue**: $49,293 for the three months ended March 31, 2025, compared to $39,679 for the same period in 2024, representing a 24.2% increase.
-   **Direct Costs**: $39,863 for the three months ended March 31, 2025, compared to $32,809 for the same period in 2024, representing a 21.5% increase.
-   **Operating Income**: $9,398 for the three months ended March 31, 2025, compared to $6,839 for the same period in 2024.

### Clinical Trials & Other Segment

-   **Revenue**: $2,045 for the three months ended March 31, 2025, compared to $2,534 for the same period in 2024, representing a 19.3% decrease.
-   **Direct Costs**: $214 for the three months ended March 31, 2025, compared to $391 for the same period in 2024, representing a 45.3% decrease.
-   **Operating Income**: $1,774 for the three months ended March 31, 2025, compared to $2,088 for the same period in 2024.

### Cash Flow

-   **Net Cash Used in Operating Activities**: -$4,988 for the three months ended March 31, 2025, compared to -$15,883 for the same period in 2024.
-   **Net Cash Used in Investing Activities**: -$202 for the three months ended March 31, 2025, compared to $19,388 provided for the same period in 2024.
-   **Net Cash Used in Financing Activities**: -$4,740 for the three months ended March 31, 2025, compared to -$938 for the same period in 2024.

### Future Outlook and Strategy

-   **Core Business Focus**: The company has implemented initiatives to reduce costs and more effectively manage working capital, resulting in an 11% reduction in SG&A expenses compared to the prior year same quarter.
-   **Non-Core Business**: The company entered into a Research Services Agreement with Helios CR, Inc., effective May 5, 2025, where the Clinical Trials segment will be operated by Helios under a profit-sharing arrangement.

### Related Stocks

- [TOIIW.US](https://longbridge.com/en/quote/TOIIW.US.md)
- [STLNW.US](https://longbridge.com/en/quote/STLNW.US.md)